Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

134.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,982
Open 134.36
Bid (Size) 134.00 (100)
Ask (Size) 135.00 (100)
Prev. Close 134.36
Today's Range 134.36 - 134.36
52wk Range 104.46 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC... 
Via MarketBeat
News headline image
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
+10.5%
+10.5%
1 Month
+5.2%
+5.2%
3 Month
-10.3%
-10.3%
6 Month
+7.3%
+7.3%
1 Year
+23.2%
+23.2%

More News

Read More
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health ↗
Via Chartmill
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance ↗
Via Chartmill
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Compugen Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline ↗
Via MarketBeat
News headline image
3 Market-Beating Stocks to Research Further
Via StockStory
News headline image
Gilead Prices $3 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗
Via MarketBeat
News headline image
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead (GILD) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
Via StockStory
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
Via StockStory
News headline image
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy ↗
Via Investor's Business Daily
News headline image
Gilead Sciences Announces First Quarter Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Via Benzinga
News headline image
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 134.36
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 05/22/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 168.46B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 168B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.